Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II study-Reference-Cited by-同舟云学术

Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II study

Published:2020-03 Issue:3 Volume:52 Page:347-350
ISSN:1590-8658
Container-title:Digestive and Liver Disease
language:en
Short-container-title:Digestive and Liver Disease

Author:

Randrian Violaine,Adenis Antoine,Desrame Jérôme,Barbier Emilie,Di Fiore Frédéric,Lièvre Astrid,Dahan Laetitia,Laurent-Puig Pierre^ORCID,Mineur Laurent^ORCID,Breysacher Gilles,Roquin Guillaume,Louafi Samy,Lopez Anthony,Louvet Christophe,Borg Christophe,Metges Jean Philippe,Faroux Roger,Gaba Lila,Manfredi Sylvain^ORCID,Tougeron David^ORCID

Funder

Servier

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference29 articles.

1. Institut National du Cancer. Les cancers en France en 2018 - L’essentiel des faits et chiffres (édition 2019).

2. Survival of patients with esophageal and gastric cancers in Europe. EUROCARE Working Group;Faivre;Eur J Cancer,1998

3. EUROCARE-4. Survival of cancer patients diagnosed in 1995–1999. Results and commentary;Sant;Eur J Cancer,2009

4. Survival for esophageal, stomach and small intestine cancers in Europe 1999–2007: results from EUROCARE-5;Anderson;Eur J Cancer,2015

5. Global incidence of esophageal cancer by histological subtype in 2012;Arnold;Gut,2015

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Esophageal cancer - French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFP, RENAPE, SNFCP, AFEF, SFR);Digestive and Liver Disease;2023-12

2. SHR‐1316 , an anti‐PD‐L1 antibody, plus chemotherapy as the first‐line treatment for advanced esophageal squamous cell carcinoma: A multicentre, phase 2 study;Thoracic Cancer;2021-03-24